
Can Medicare Sustain Widespread Access to GLP-1 Therapies?
Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access,
The American Journal of Managed Care